The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...

The first fixed-dose combination pill containing 3 drugs has been approved for use in the United States by the US Food and Drug Administration (FDA). Exforge HCT®, which is marketed by Novartis, ...

With Teva being the first to file, the company will enjoy 180 days of marketing exclusivity. As per IMS data, Exforge HCT tablets recorded annual sales of approximately $158 million in the U.S. as of ...

The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Exforge HCT® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets in the ...

Novartis has received a major boost in the USA after regulators there gave their backing to two of the Swiss major’s combination high blood-pressure drugs which can now be used as first-line ...

LONDON (MarketWatch) -- Novartis said Monday that the U.S. Food and Drug Administration has approved two of its single-pill combination medicines as initial therapies for patients likely to need more ...

Approvals consistent with current US treatment guidelines to start appropriate patients on combination therapies[1] Up to 80% of patients may need multiple medications to help them reach blood ...

Teva Pharmaceutical Industries Limited ( TEVA) has launched its generic version of Novartis' ( NVS) Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the U.S. Exforge HCT is approved ...